Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.76 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | PPARG | P37231 | 5/20 | 0.76 |
| ▸ | OXER1 | Q8TDS5 | 4/20 | 0.76 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.76 |
| ▸ | RXRA | P19793 | 2/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.61 |
| ▸ | F7 | P08709 | 3/20 | 0.61 |
| ▸ | F3 | P13726 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | PPARD | Q03181 | 3/20 | 0.61 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23646056 | 1.00 | ALDH1A1 (0.76) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL23646062 | 1.00 | ALDH1A1 (0.76) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL23646058 | 1.00 | ALDH1A1 (0.76) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL29580115 | 0.90 | ALDH1A1 (0.77) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL29557124 | 0.90 | ALDH1A1 (0.77) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL23646064 | 0.90 | ALDH1A1 (0.77) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL19972590 | 0.90 | ALDH1A1 (0.59) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL3408505 | 0.87 | ALDH1A1 (0.79) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| Doconexent SCHEMBL18185428 | 0.87 | ALDH1A1 (1.00) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| Doconexent SCHEMBL288437 | 0.87 | ALDH1A1 (1.00) | ALDH1A1CYP19A1MAPTPPARGOXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | claimed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | claimed |
| CN-118714935-A | Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment | 阿马里纳药物爱尔兰有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-20240201207-A1 | METHOD AND KIT FOR PREDICTING PREECLAMPSIA | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2024-06-20 | — | — | US | claimed |
| EP-4327105-A1 | METHOD AND KIT FOR PREDICTING PREECLAMPSIA | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2024-02-28 | — | — | EP | claimed |
| WO-2023192314-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | claimed |
| WO-2022223542-A1 | METHOD AND KIT FOR PREDICTING PREECLAMPSIA | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-10-27 | — | — | WO | claimed |
| EP-4080220-A1 | METHOD AND KIT FOR PREDICTING PREECLAMPSIA | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2022-10-26 | — | — | EP | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| EP-3892608-B1 | NOVEL N-3 IMMUNORESOLVENTS: STRUCTURES AND ACTIONS | BRIGHAM & WOMENS HOSPITAL INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250216407-A1 | LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS | INIPHARM, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4468884-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | Amarin Pharmaceuticals Ireland Limited (IE) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146984-A1 | LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-03 | — | — | WO | disclosed |
| US-11667598-B2 | N-3 immunoresolvents: structures and actions | THE BRIGHAM & WOMEN'S HOSPITAL INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2022223542-A1 | METHOD AND KIT FOR PREDICTING PREECLAMPSIA | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-10-27 | — | — | WO | disclosed |
| EP-4080220-A1 | METHOD AND KIT FOR PREDICTING PREECLAMPSIA | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2022-10-26 | — | — | EP | disclosed |
| US-11426385-B2 | Methods of improving cancer chemotherapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210223269-A1 | BIOMARKERS FOR DETECTION OF CORONARY ARTERY DISEASE AND ITS MANAGEMENT | OREGON STATE UNIVERSITY (US) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | ALDH1A1 266/4885CYP19A1 763/4885MAPT 2470/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | ALDH1A1 756/4885CYP19A1 21/4885MAPT 2450/4885 |
| US-11667598-B2 | N-3 immunoresolvents: structures and actions | HPGDS, ALOX5, ALOX15B | ALDH1A1 760/4885CYP19A1 1678/4885MAPT 4861/4885 |
| US-11426385-B2 | Methods of improving cancer chemotherapy | ALOX5, EPHX1, ALOX12 | ALDH1A1 107/4885CYP19A1 442/4885MAPT 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.